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Abstract 
The ability to detect and quantify specific DNA adducts benefits genome stability 
research, drug development and the evaluation of environmental mutagens. The TARDIS 
assay was developed as a means of detecting and quantifying melphalan and cisplatin DNA 
adducts at the single cell level and has since been adapted to quantify topoisomerase DNA 
complexes. The method relies on salt-detergent extraction of agarose-embedded cells. 
Genomic DNA and any covalently attached molecules remain in place in the agarose, while 
other cellular constituents are removed. Drug-DNA or topoisomerase-DNA complexes are 
then detected and quantified by sensitive immunofluorescence using adduct-specific 
antibodies. Here we give a perspective of the TARDIS assay including a comparison with 
other methods for quantifying topoisomerase-DNA covalent complexes and provide technical 
details required to set up and perform the assay. 
 
 
2 
Original development – quantification of melphalan DNA adducts at the 
single-cell level 
 
The development of monoclonal antibodies that recognised DNA adducts formed by 
the anticancer drugs melphalan and cisplatin (1-2) led to the desire to apply these to quantify 
drug-DNA adducts in individual cells to enable the study of small samples, the assessment of 
heterogeneity in damage formation and repair within a cell population , and also offered the 
potential to study spatial distribution of adducts across tissue sections. However, for 
conventionally fixed cells or tissues there are two challenges to such analyses. Firstly, access 
of antibody to DNA adducts could be hindered by DNA-associated proteins. Secondly, 
antibodies often only recognise adducts in denatured DNA. Therefore it was essential to 
achieve efficient denaturation of the DNA without causing loss of material from the 
microscope slide. These factors raised concerns about the reliability of any conventional 
approach to immunostaining because differences between cell types and/or changes to the 
structure of chromatin in response to DNA damage formation, could affect the efficiency of 
any immunostaining procedure. Hence, if conventional immunostaining methods were to be 
used, one would need to be sure that any differences between cells truly reflected differences 
in adduct levels and not differences in detection efficiency resulting from differences in 
accessibility to antibody or because it’s DNA was more readily denatured (e.g. there was a 
nearby single strand break, as discussed below). Another complicating factor is that adduct 
levels need to be assessed in relation to a reliable measurement of DNA content. Otherwise, 
one cell could appear as carrying more adducts than another simply because it was in G2 
rather than G1 phase of cell cycle or because it was aneuploid rather than diploid.  
 
The technique that was subsequently named the Trapped in Agarose DNA 
ImmunoStaining (TARDIS) method was initially conceived as a way to overcome these 
challenges. The idea for the method came to MJT in 1989 whilst watching the preparation of 
agarose sample plugs for use in pulse field gel electrophoresis in which the intact human 
DNA molecules are too large to diffuse through agarose and so remained trapped, whilst the 
porosity of the agarose was sufficient to readily permit diffusion of proteins such as 
nucleases. If the agarose could be spread on a microscope slide in a thin layer, it might be 
possible to retain DNA from individual cells whilst achieving efficient removal of essentially 
all cellular proteins. Such pure DNA would then be amenable to rapid alkaline-denaturation 
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and subsequent immunofluorescent staining. Also, DNA could be quantified through the use 
of suitable fluorescent dyes. Finally, the absence of other cellular material could result in 
lower levels of non-specific staining. Early versions of the COMET assay, available at that 
time, indicated procedures for spreading and retaining agarose onto microscope slides.   
 
Initial attempts to apply this approach focused on using antibody CP9/19 (2) to detect 
DNA adducts formed by cisplatin. Initially this worked very well using a standard 
fluorescence microscope. Immunofluorescence intensity increased in proportion to the 
cisplatin concentration to which cells had been exposed, from an essentially undetectable 
level for control cells. It also worked well in the laboratory of Dr. P. Twentyman, where 
analysis was by confocal microscopy. However, subsequent attempts to apply this method 
were unsuccessful because of persistent high levels of non-specific binding of primary 
antibody to DNA from control cells. Despite numerous attempts, this problem could not be 
overcome. Work then focussed on applying the TARDIS assay to measurement of 
melphalan-DNA adducts using antibody MP5/73 (1) and in this case the method worked very 
reliably. It was known from ELISA experiments with antibody MP5/73 that to attain 
maximum adduct recognition it was necessary to denature the DNA. This property was easily 
confirmed using the TARDIS method. By having DNA trapped in agarose on a slide it was 
easy to investigate the effect of different alkali exposures. Such optimisation was important 
because over-exposure to alkali can cause chemical conversion of melphalan-guanine adducts 
to the ring-opened form which were known not to be recognised by this antibody. In fact the 
TARDIS assay was later applied to detect the alkali-induced ring-opened adducts by using a 
different antibody that does recognise these structures (3). Further studies revealed that 
optimum detection of melphalan adducts through DNA denaturation could be influenced by 
the level of strand breaks in the DNA (4). This is explicable, knowing that very large DNA 
molecules take long times to unwind and fully separate into single strands because unwinding 
takes place only from the ends. Until it is fully unwound, DNA can rapidly re-nature upon 
neutralisation (5). An increase in frequency of strand breaks (single or double) increases the 
number of points from which DNA can unwind thereby accelerating the overall rate of 
denaturation.  Ionising irradiation increased the overall sensitivity of immunological 
detection of melphalan-DNA adducts and this was attributed to the introduction of strand-
breaks. In addition, radiation decreased the extent of inter-cell heterogeneity in 
immunostaining for melphalan adducts. This indicated that, even in the TARDIS method 
where DNA is stripped of other macromolecules, differences between cells in 
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immunostaining can result from differences in DNA conformation rather than differences in 
actual adduct levels. This illustrates the caution needed in interpreting any immunostaining 
method for DNA adducts where the binding of the antibody used is known to be influenced 
by DNA conformation. It seems that the same factors will also influence adduct detection in 
conventionally fixed specimens, but it is only in the TARDIS method that they can be 
directly investigated. 
 
Wider current and potential applications. 
The TARDIS method can, in principle, be applied to any immunologically detectable adduct. 
Detection of low molecular weight adducts such as those formed by melphalan, are more 
likely to be affected by DNA conformation. The opposite extreme of adduct size is the 
covalent binding of proteins to DNA and in such cases it is seems less likely that 
immunological detection will be significantly influenced by underlying DNA conformation. 
The most studied examples of protein adducts are the topoisomerase II complexes which are 
discussed in detail below.  However, it could, in principle, be applied to the detection of other 
proteins that become covalently bound to the genome such as stalled intermediates of other 
DNA-modifying enzymes and protein cross-linked to DNA by experimental or therapeutic 
chemicals or by oxidative damage. Here, it is worthwhile pointing out that the TARDIS assay 
is currently the only available method that permits measurement specifically of protein-DNA 
adducts in individual cells since, unlike low molecular weight DNA adducts, it is necessary to 
efficiently remove all of the normally present but non-covalently bound protein whilst 
retaining all the DNA. Studies referred to above, in which the effect of alkali treatment of 
melphalan adducts was determined, illustrate the principle that the TARDIS method can 
permit additional investigations. Since the principle of the method is to allow quite large 
proteins (antibodies) to access trapped DNA adducts, there is the possibility of carrying out 
enzymatic as well as chemical alterations to the DNA modifications being investigated. 
Comparison of immunofluorescent staining with and without such a treatment could provide 
information about the nature of the target modification such as its susceptibility to specific 
DNA glycosylases or proteases. For example, enzymatic treatment of COMET slides with 
glycolases has been reported previously as a means of detecting specific DNA lesions(6). 
 
Key factors and limitations 
One obvious limitation of the TARDIS method is that it does not permit analysis of cells in 
the context of tissue architecture in a section. However, analysis of cells microdissected from 
5 
frozen sections could be feasible. The staining procedures for melphalan adducts all make use 
of antibodies of the IgG class. This is likely to be an important property because, in addition 
to such antibodies tending to show higher affinities, the high molecular weight of antibodies 
of classes such as IgM could hamper penetration into the agarose. In order to detect low 
levels of DNA modifications, it is, of course, essential that the antibody shows high affinity 
for the modification and low non-specific binding. However, unlike conventional 
immunohistochemistry or immunoblotting procedures, TARDIS preparations contain 
essentially no cellular material other than the DNA and so the main cause of non-specific 
binding is absent. More of concern is that there should be very low cross-reactivity with 
normal DNA. Detection of low molecular weight adducts is more likely to be challenged by 
this factor than detection of large adducts such as proteins. However, efficiency of detection 
of proteins bound to DNA, particularly if a monoclonal antibody is used, is likely to be 
influenced by location of the epitope which could be masked it were close to, or within, the 
DNA binding site. A range of antibodies have been used for TARDIS to detect 
topoisomerases. The majority of antibodies that have worked well in TARDIS are rabbit 
polyclonal antibodies and details are given in the relevant primary publications. 
 
The relative sensitivity of detection for topoisomerase adducts by the TARDIS method is 
discussed below but, in general, sensitivity is limited by a combination of the following 
factors: (a) The cross-reactivity and non-specific binding of primary and secondary 
antibodies. Since the DNA is essentially free of other cellular material, non-specific binding 
should be very low. (b) Intensity and stability of excitation light. These factors are both 
optimised by use of a xenon arc lamp or metal halide illumination (see section on microscope 
specifications below). (c) The back-ground light level in the optics of the microscope. This is 
determined by the efficiency of the excitation and emission filters and also by features such 
as the glass and adhesives used to manufacture of the objectives.  (d) Accuracy of 
quantification is determined partly by the stability of the light supply, but also by the 
uniformity that the light can be distributed to and collected from all regions of the captured 
image field. Image correction (described below and in ref (7)) can attempt to correct for non-
uniformities in these parameters but this far from perfect. 
 
 The development of automated laser scanning microscope-based imaging systems offers the 
prospect of both reduced background light (as a result of confocal optics), higher excitation 
intensity and more accurate quantification. Also, automated analysis of large numbers of cells 
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and slides would be a major advantage and would enable high throughput screening for new 
compounds targeting topoisomerases or testing procedures for potential topoisomerase-
mediated genotoxicity. 
Unlike the standard COMET assay, the TARDIS method detects specific modifications rather 
than the presence of general DNA breakage or cross-linkage. It could be of interest to 
combine TARDIS and COMET assays to investigate the distribution of adducts at different 
points in the DNA COMET head and tail. Indeed, immunofluorescent staining for 
topoisomerase IIhas been combined with COMET analysis (8)However, detection 
sensitivity for adducts in the tail may be limited because detection sensitivity is greatest when 
DNA concentration is maximised by retaining it in a concentrated spot. In this situation, the 
ratio of immunostaining to background fluorescence signals is maximal.   
 
Analysis of topoisomerase II – DNA adducts 
Following its development to quantify low MW DNA adducts the  trapped in agarose 
immunostaining method was adapted to study topoisomerase II adducts. Human DNA 
topoisomerase II is the target for a number of anti-cancer drugs including etoposide, 
mitoxantrone, mAMSA, daunorubicin, doxorubicin and idarubicin. These drugs act by 
stabilising a normally transient DNA-topoisomerase reaction intermediate and are termed 
topoisomerase poisons (9). Type II DNA topoisomerases generate a transient enzyme-bridged 
DNA double-strand break through which a second duplex can be passed (strand-passage). At 
this stage in the reaction cycle the enzyme is covalently coupled to the DNA through a 
phospho-tyrosine linkage. After strand passage the break is rejoined (10-12). However, the 
rejoining step is blocked by topoisomerase poisons, leading to accumulation of stabilised 
topoisomerase II-DNA complexes. The transient reaction intermediates between DNA and 
the topoisomerase have been referred to as “cleavable complexes” ”(9) since addition of SDS 
and proteinase K to these complexes produces a cleaved DNA.   
 
Human cells contain two topoisomerase II isoforms, topoisomerase II and 
topoisomerase II. In vitro cleavage assays showed that both isoforms form drug stabilised 
cleavable complexes (13-14).  To study the isoform-specific effects of drugs in cells we 
adapted the TARDIS assay to allow isoform-specific detection of topoisomerase II DNA 
adducts (15), an outline of the methodology is shown in Figure 1. This study showed for the 
first time that both topoisomerase isoforms could form DNA complexes when human cells 
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were exposed to etoposide (15). The stabilised complexes increased in a dose-dependent 
manner and were detectable after a two hour treatment with 1M etoposide. The rate of 
disappearance of etoposide-stabilised topoisomerase II complexes after drug removal was 
analysed and the half life found to be 30 min for topoisomerase II and 15 min for 
topoisomerase II. The TARDIS assay has subsequently been used to assess topoisomerase II 
adducts levels in human and murine cell lines exposed to a number of compounds listed in 
Table 1. Both topoisomerase II isoforms formed stabilised complexes with DNA when cells 
were treated with mAMSA or mitoxantrone. The half life of the mAMSA stabilised 
complexes following drug removal was 15 minutes for both the alpha and beta isoforms. In 
contrast the half life of complexes following mitoxantrone removal was 6  
 hours for beta and 10 hours for alpha. Only topoisomerase II complexes could be detected 
following exposure to anthracyclines such as doxorubicin, daunorubicin and idarubicin. 
Following removal of idarubicin from the cell culture media the levels of complexes 
continued to rise for at least 48 hours. Two alkylating anthraquinones, Alchemix and ZP275 
preferentially stabilised topoisomerase II complexes (16), as did DACA and TAS-103 (17). 
NK314 a synthetic benzo[c]phenanthridine alkaloid targets topoisomerase II preferentially 
(18). A number of naturally occurring compounds including selenite, curcumin, digitoxin and 
dietary flavonoids stabilise topoisomerase II complexes and have been analysed using the 
TARDIS assay assay (18-24) ( see Table 1).  The TARDIS assay has also been used to detect 
topoisomerase I complexes in response to camptothecin (25) and other compounds (22-23,26-
29). Other groups have used the TARDIS assay (30-32). 
 
Variations 
Embedding suspension cells or trypsinised adherent cell culture cells in agarose on a glass 
slide allows the use of harsh extraction conditions which strips away essentially all non-
covalently attached cellular material, leaving genomic DNA and covalent adducts for 
analysis. This protocol, employed in the TARDIS assay, results in low background signals in 
untreated cells and corresponding high sensitivity. One variation described by Agostinho et al 
(33) utilises less harsh extraction conditions to remove most topoisomerase II not covalently 
attached or trapped in closed clamp form on the genomic DNA from adherent cells grown on 
glass slides or coverslips. Under these conditions extracted cells and their genomic DNA 
remain attached without the need for agarose embedding. In our hands this method suffers 
from higher background levels of topoisomerase fluorescence in untreated cells making it less 
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suitable than the standard TARDIS assay for quantitative analysis. However, it has been used 
successfully by Agostinho et al and ourselves to examine the distribution in the nucleus of 
topoisomerase II – DNA complexes induced by topoisomerase poisons or the topoisomerase 
inhibitor ICRF193. 
 
Other methods to study topoisomerase II DNA adducts 
There are a number of other techniques that have been used to detect and quantify 
topoisomerase - DNA complexes; these include the SDS-K precipitation method (34), 
alkaline elution (35), ICE bioassay (36) and band depletion (37). The SDS-K precipitation 
and alkaline elution methods are the most sensitive, however they lack specificity for 
topoisomerases as any protein-DNA complexes can give a signal and they both also rely on 
the use of radioactive labelling.  The TARDIS assay, ICE-bioassay and band depletion are 
more specific for topoisomerase, and since they use an antibody detection step they can each 
be used to detect specific topoisomerase isoforms. The TARDIS and ICE bioassays are 
comparable in terms of their sensitivity, and both are much more sensitive than band 
depletion.  Band depletion in K562 cells requires >200 M etoposide to obtain significant 
depletion of topoisomerase II, whereas the TARDIS assay gives an above background signal 
with 1M for topoisomerase II, and a robust signal for both isoforms from 10M. ICE 
bioassay gave good signals at 100M (18,36). For topoisomerase I, 25 M camptothecin 
gave a 50% reduction in band depletion (26), yet only 1M was needed to give a 
reproducible signal in the TARDIS assay (25-26). 10M topotecan gave a strong ICE 
bioassay signal (36). 
 
The TARDIS assay is the only one of these assays that detects complexes in 
individual cells and it requires orders of magnitude fewer cells per assay. This makes it 
applicable for use on samples from patients during therapy where cell numbers are likely to 
be limited. For example, AML cells treated ex vivo with camptothecin showed a dose 
dependent increase in topoisomerase I complexes (25). Samples from patients after treatment 
with etoposide have also been analysed (unpublished). The TARDIS assay has also been used 
to study drug resistant cells lines and to compare the parental sensitive line with the selected 
drug resistant line. This showed a reduction in topoisomerase II complexes in lines resistant 
to topoisomerase II drugs (unpublished data).  
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The TARDIS assay is based on immunofluorescent detection of protein (or DNA-
reactive drug) adducts that are covalently coupled to DNA. Such complexes are formed with 
topoisomerase poisons such as etoposide, mAMSA or mitoxantrone as discussed above. In 
these cases, the topoisomerase complexes are reversible upon removal of drug. However, 
topoisomerases (and other chromatin proteins) can also become crosslinked to genomic DNA 
by compounds that generate reactive oxygen species (ROS). These crosslinked complexes are 
effectively irreversible in the cell. Thus, the propensity of a compound to generate stabilised 
topoisomerase-DNA complexes through enzyme poisoning or lead to ROS-mediated 
crosslinked topoisomerase II-DNA complexes can be distinguished by reversibility studies 
and the inclusion of antioxidants such as N-acetylcysteine (23). 
Comparisons with other methods of assessing genotoxicity indicates that the TARDIS 
assay has a similar level of sensitivity to the micronucleus assay, comet assay and 
phosphorylated histone H2AX assay (38).  A modified comet assay has been reported where 
the cells were probed with topoisomerase II antibodies to determine if there were any DNA 
adducts in the comet tail (8). 
There are a range of other uses of the TARDIS assay. It can be used to analyse adduct 
removal mechanisms in vitro. We have used topoisomerase II adducts on genomic DNA 
within agarose on slides as a substrate; addition of enzymes to the slides and incubation has 
been used to determine which proteins are able to remove the toposiomerase II protein. 
Covalent modifications of toposiomerase could be investigated. Preliminary experiments 
detected sumyolated proteins (26) and it could be used to detect phosphorylated 
toposiomerase II or acetylated topoisomerase II if appropriate antibodies were available.  
We give details of the preparation of slides for TARDIS analysis, equipment and 
software requirements and the method of data analysis in sections below. 
 
TARDIS equipment and procedure 
Preparing slides 
No specialist equipment is required for the preparation of slides for analysis. A 
detailed protocol is given in the supplementary material. Briefly, cultured cells are plated into 
six well plates and exposed to the drug under study. At the end of the exposure period the 
cells are washed and suspended in molten LMP agarose at 37. This cell suspension is then 
spread as a thin layer onto glass slides. The agarose-embedded cells are then extracted with 
ionic detergent and salt to remove proteins and other molecules not covalently bound to 
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DNA. After washing to remove salt and detergent, slides are processed for 
immunofluorescence for the protein or molecule of interest. Counterstaining with Hoechst 
allows the localisation of extracted nuclei on the slide. The TARDIS protocol is outlined in 
Figure 1A. Use of a conventional immunofluorescence microscope has proved adequate for 
many studies, however, to attain useful detection sensitivity and accuracy certain equipment 
details need to be considered (see more below under microscope and camera specifications).  
Typically, the immunofluorescent stage employs an unlabelled primary antibody and 
fluorescently labelled secondary antibody. We have traditionally used FITC-labelled second 
antibodies but other fluorochromes such as AlexaFluor488 (Invitrogen) would also be 
suitable. Monochrome images are recorded for the Hoechst and FITC channels using 
appropriate narrow-band filter sets for each field of cells. Examples of topoisomerase II 
TARDIS images collected for etoposide-treated K562 cells are shown in Figure 1B. 
Image analysis 
Image analysis consists of three stages. Firstly, images are background and shade 
corrected to correct for stray light and background originating in the camera electronics and 
for unevenness in the intensity of illumination respectively. Secondly, the area corresponding 
to each nucleus is identified using the Hoechst image to generate a mask around each 
nucleus. This mask is applied to the FITC image and parameters including number of pixels 
and average pixel intensity are measured for each masked area (nucleus). In the third stage, 
these data are exported into a spreadsheet, typically to calculate total FITC and Hoechst 
intensities measured for each nucleus and this data is represented graphically. An example of 
the type of output obtained is shown on Figure 1C. We currently use Volocity software 
(Perkin Elmer) for image management and analysis. A flow diagram for the image analysis is 
given in Figure 2.  
The following points need to be considered carefully for successful quantitative 
immunofluorescence: (a) Exposure time. Exposure times must be sufficiently long to record 
a robust fluorescent image from the brightest samples, typically in the range of 100mS to 2S 
for topoisomerase TARDIS, depending on the sample, camera and optics; but the brightest 
images in a set must not saturate the recording device. This can be checked by taking the 
sample with the brightest signal or a bright control (for example cells treated with 100 
etoposide for topoisomerase II TARDIS) and recording a consecutive series of images at 
increasing exposures. Plotting the median fluorescence per nucleus should give a linear 
response against time. Choose an exposure within the linear part of the response. (b) 
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Bleaching. The above discussion does not take into account fluorescent bleaching of the 
sample, which may result in lower fluorescent values than expected at longer exposures. 
Once an optimum exposure is selected in (a) above, record two consecutive images from a 
single field of cells at that exposure. Both images will give equivalent median fluorescence 
values unless significant bleaching has occurred. If the second exposure results in 
significantly reduced fluorescence, consider reducing excitation intensity or use of a more 
photostable fluorochrome. (c) Background and shade correction. It is important to 
minimise the effect of background signal arising from camera electronics, stray light and 
background fluorescence. This is achieved by recording FITC and Hoechst images from a 
blank slide, or preferably a region of the sample slide containing no cells. This “Dark 
Reference” image is recorded using the same settings including exposure time as the sample 
slides. This allows subtraction of the background image from the sample images. Any 
unevenness in the illumination of the sample is minimised using a shade correction. For this 
an image of an evenly fluorescent sample is recorded. This can be achieved using fluorescent 
plastic slides or solutions of 3M fluorescein and 200M 4-methylumbeliferone in 20m-
deep observation chambers (7). These images are called “Bright Reference” images. The 
intensity of each pixel in the bright reference image is divided by the mean of all of the pixels 
in the image. The resulting ratios corresponding to each pixel in the reference image are used 
to correct the corresponding pixels in each sample image. In practice, software such as 
Volocity allows the user to assemble combined background and shade corrections for each 
channel (FITC and Hoechst) using the dark and bright reference images and apply this 
correction to the sample images in one go. The means of achieving this will differ between 
software packages. (d) Internal standards and controls. It is useful to include a positive 
control or internal standard in each set of slides to facilitate comparison between individual 
experiments. We generally include 100M etoposide-treated cells as a positive control for 
topoisomerase II TARDIS. An alternative approach would be to use fluorescent beads that 
are available from suppliers such as Invitrogen.  
Microscope specifications. 
We have used two quite different conventional microscope platforms for quantitative 
immunofluorescence. The main specific requirements are as follows: (1) good quality planar 
apochromatic high NA 10X and / or 20X objectives with low levels of autofluorescence 
associated with the glass and adhesives used to assemble the lenses; (2)  a bright stable 
fluorescent light source ideally a xenon arc lamp or metal halide arrangement such as anX-
12 
cite system (EXFO), suitable narrow band filter sets for FITC (or other fluorochrome) and 
Hoechst fluorescence and sensitive monochrome cooled CCD camera (see below). Systems 
can be motorised or fully manual, though considerable time can be saved during image 
acquisition through partial automation with a motorised system. Specifications for the 
original system used are described by Frank et al (7) and we also use a similar system based 
on a Leica DMLB microscope. Recently we have also employed an Olympus IX81 motorised 
microscope (see Table 2) 
Camera specifications 
Fluorescence arising from DNA adducts is faint compared to typical 
immunofluorescence of cellular structures in normally fixed cells, so a sensitive monochrome 
camera system is required. In the system described by Frank et al (4) for the detection of 
melphalan adducts, images were captured using a cooled slowscan CCD with 16-bit (64,000 
greyscale) output and 770x1152 pixels (Astrocam). A similarly specified recent model is the 
Hamamatsu Orca II BT 1024 (see Table 2). For quantification of topoisomerase DNA 
complexes, as well as the above-mentioned system we have used both Hamamatsu ORCA-
AG and Photometrics Coolsnap HQ2 cameras. Both of these cameras employ cooled CCDs 
with 6.45m photosites and 12/14-bit AD conversion. Other required characteristics for 
TARDIS or indeed any quantitative immunofluorescence analysis include: high quantum 
efficiency, large photosite full-well capacity and low dark current. These attributes relate to 
efficiency of converting photons to electrons at the photosite, number of electrons to “fill” the 
photosite and accumulation of electrons at photosites in the absence of illumination (thermal 
noise) respectively. Camera models are continually being updated by manufacturers, but 
some values for the above attributes are given in Table 3 as a guide. Suitable image sensors 
contain about a million photosites (1 megapixel), and are operated in 2x2 binning mode, 
whereby 2x2 squares of photosites acts as a single entities. 
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Figure Legends 
 
Figure 1 Basis of TARDIS analysis (A) Schematic diagram of the steps involved in processing cells for 
TARDIS analysis: (1) Cells are embedded in agarose on a glass slide; (2) After extraction with SDS and 
salt most cellular components are removed but genomic DNA and covalent  adducts remain; (3) Adducts 
are detected by immunofluorescent staining using specific primary antibodies and FITC-labelled secondary 
antibody; (4) Areas occupied by genomic DNA are identified by Hoechst fluorescence; (5) FITC 
fluorescence is quantified within the areas defined as containing DNA. (B) Representative images recorded 
for etoposide-treated K562 cells. Immunofluorescence was carried out with anti-topoisomerase II and 
FITC-conjugated second antibody. (C) Scattergram representation of the topoisomerase II signal derived 
from etoposide-treated K562 cells.  Each filled circle represents the integrated fluorescence value of a 
single nucleus. The horizontal lines represent the median values. 
 
Figure 2.  Flow diagram for TARDIS image capture and analysis. 
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Drug Cell lines TARDIS DATA 
 
Ref 
  T2 
Poison 
 
T2 
Poison 
 
T2 
Catalytic 
Inhibition 
Topo I  
Etoposide CEM, MEFs yes yes   (12,16-17) 
NK314 MEFs yes yes   (15) 
Mitoxantrone CEM, MEFs yes yes   (16-17,39) 
mAMSA MEFs yes yes   (16-17) 
Idarubicin K562 yes yes yes  (18) 
Idarubicinol K562 yes yes   (18) 
Selenite K562 yes yes  yes (19) 
Digitoxin K562 yes yes yes  (25-26) 
Curcumin K562 yes yes  yes (20) 
Ferulic acid K562 no no  no (20) 
dibenzoylmethane K562 no no  no (20) 
Genistein K562 yes yes  no (40) 
luteolin K562 yes yes  no (40) 
Quercetin K562 yes yes  no (21) 
Apigenin K562 yes yes  no (21) 
Fisetin K562 no no yes no (21) 
Myricetin K562 yes yes  yes (21) 
EGCG K562 yes yes  yes unpublished 
H202 K562 yes yes  yes unpublished 
Camptothecin CEM    yes (22) 
DACA CEM yes yes  no (14) 
TAS-103 CEM yes yes  yes (14) 
XR5944 K562 yes yes  yes (23) 
XR11576 K562 yes yes  yes (23) 
ICRF193 MEFs, K562 yes yes yes  unpublished 
Aclarubicin MEFs   yes  unpublished 
Merbarone MEFs   yes  unpublished 
Intoplicine MEFs   yes  unpublished 
Novobiocin MEFs   no  unpublished 
Suramin MEFs   no  unpublished 
Table 1. Examples of TARDIS analyses for topoisomerase II or - poisoning or catalytic 
inhibition and for topoisomerase I. 
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System Leica DMLB Olympus IX81 
Operation Manual Motorised  / automated 
Illumination 75W Xenon Metal Halide X-cite120Q 
Filters Narrow band pass “filter cubes” Narrow band pass “filter cubes” 
Objectives (suitable for TARDIS) 10X HC PL APO NA 0.4 
20X HC PL APO NA 0.7 
10X VPLA FL NA 0.3. 
Camera Photometris Coolsnap HQ2 Hamamatsu Orca-AG 
Table 2. Microscope specifications used for topoisomerase TARDIS 
 
 
 
 Orca-BTII 1024 
 Hamamatsu 
Orca-AG 
Hamamatsu 
Coolsnap HQ2 
Photometrics 
Photosite size 13 x 13 m 6.45 x 6.45m 6.45 x 6.45 m 
No of pixels 1024 x 1024 1344 x 1024 1393 x 1040 
AD conversion 16 bit 12 or 16 bit 14 bit 
Full-well capacity 80K e
-
 18K e
-
 16K or 30K e
-
 binned 
Dark current 0.01 e
-
 /pixel/ s 0.03 e
-
 /pixel/ s 0.001 e
-
/pixel/s (-30C) 
Table 3. Camera characteristics (Data from manufacturer’s datasheets) 
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